TY - JOUR
T1 - Vascular endothelial growth factor (VEGF) inhibitorsin cancer therapy
T2 - An update
AU - Homsi, Jade
AU - Kim, Lori C.
AU - Munster, Pamela N.
AU - Chodkiewicz, Catherine
AU - Daud, Adil
PY - 2006/1/1
Y1 - 2006/1/1
N2 - Recent progress in the molecular and biological understanding of the VEGF pathway provides us with novel and promising therapeutic strategies and targets for overcoming cancer. VEGF plays an important role in tumor growth and metastasis. It is recognized as an essential regulator of normal and abnormal blood vessel growth. Therapies designed to target VEGF have been in development for the past few years and as a result VEGF inhibitors are now available as standard therapy or as part of clinical trials. Bevacizumab was the first anti-VEGF therapy and was approved for use in metastatic colorectal cancer after showing significant improvement of survival. Recent trials with several VEGF inhibitors in breast, non-small cell lung, ovarian, kidney cancers and melanoma have shown very encouraging results. This review will discuss the role of VEGF in angiogenesis and malignancy, VEGF inhibitors, and the recent clinical trials of their use in different tumors.
AB - Recent progress in the molecular and biological understanding of the VEGF pathway provides us with novel and promising therapeutic strategies and targets for overcoming cancer. VEGF plays an important role in tumor growth and metastasis. It is recognized as an essential regulator of normal and abnormal blood vessel growth. Therapies designed to target VEGF have been in development for the past few years and as a result VEGF inhibitors are now available as standard therapy or as part of clinical trials. Bevacizumab was the first anti-VEGF therapy and was approved for use in metastatic colorectal cancer after showing significant improvement of survival. Recent trials with several VEGF inhibitors in breast, non-small cell lung, ovarian, kidney cancers and melanoma have shown very encouraging results. This review will discuss the role of VEGF in angiogenesis and malignancy, VEGF inhibitors, and the recent clinical trials of their use in different tumors.
UR - http://www.scopus.com/inward/record.url?scp=85027916117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027916117&partnerID=8YFLogxK
U2 - 10.3109/14733400600739731
DO - 10.3109/14733400600739731
M3 - Review article
AN - SCOPUS:85027916117
SN - 1473-3404
VL - 6
SP - 127
EP - 136
JO - Women's Oncology Review
JF - Women's Oncology Review
IS - 42067
ER -